Large-scale circulating proteome association study (CPAS) meta-analysis identifies circulating proteins and pathways predicting incident hip fractures.

LXR/RXR hip fracture meta-analysis osteoporosis proteomics

Journal

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
ISSN: 1523-4681
Titre abrégé: J Bone Miner Res
Pays: England
ID NLM: 8610640

Informations de publication

Date de publication:
04 Jan 2024
Historique:
received: 21 08 2023
revised: 09 11 2023
accepted: 23 11 2023
medline: 13 3 2024
pubmed: 13 3 2024
entrez: 13 3 2024
Statut: aheadofprint

Résumé

Hip fractures are associated with significant disability, high cost, and mortality. However, the exact biological mechanisms underlying susceptibility to hip fractures remain incompletely understood. In an exploratory search of the underlying biology as reflected through the circulating proteome, we performed a comprehensive Circulating Proteome Association Study (CPAS) meta-analysis for incident hip fractures. Analyses included 6430 subjects from two prospective cohort studies (Cardiovascular Health Study and Trøndelag Health Study) with circulating proteomics data (aptamer-based 5 K SomaScan version 4.0 assay; 4979 aptamers). Associations between circulating protein levels and incident hip fractures were estimated for each cohort using age and sex-adjusted Cox regression models. Participants experienced 643 incident hip fractures. Compared with the individual studies, inverse-variance weighted meta-analyses yielded more statistically significant associations, identifying 23 aptamers associated with incident hip fractures (conservative Bonferroni correction 0.05/4979, P < 1.0 × 10-5). The aptamers most strongly associated with hip fracture risk corresponded to two proteins of the growth hormone/insulin growth factor system (GHR and IGFBP2), as well as GDF15 and EGFR. High levels of several inflammation-related proteins (CD14, CXCL12, MMP12, ITIH3) were also associated with increased hip fracture risk. Ingenuity pathway analysis identified reduced LXR/RXR activation and increased acute phase response signaling to be overrepresented among those proteins associated with increased hip fracture risk. These analyses identified several circulating proteins and pathways consistently associated with incident hip fractures. These findings underscore the usefulness of the meta-analytic approach for comprehensive CPAS in a similar manner as has previously been observed for large-scale human genetic studies. Future studies should investigate the underlying biology of these potential novel drug targets. Hip fractures are associated with significant disability, high cost, and mortality. However, the exact biological mechanisms underlying susceptibility to hip fractures remain incompletely understood. To increase the understanding of the underlying mechanisms, we performed a meta-analysis of the associations between 4860 circulating proteins and risk of fractures using two large cohorts, including 6430 participants with 643 incident hip fractures. We identified 23 proteins/aptamers associated with incident hip fractures. Two proteins of the growth hormone/insulin growth factor system (GHR and IGFBP2), as well as GDF15 and EGFR were most strongly associated with hip fracture risk. High levels of several inflammation-related proteins were also associated with increased hip fracture risk. Pathway analysis identified reduced LXR/RXR activation and increased acute phase response signaling to be overrepresented among those proteins associated with increased hip fracture risk. Future mechanistic studies should investigate the underlying biology of these novel protein biomarkers which may be potential drug targets.

Autres résumés

Type: plain-language-summary (eng)
Hip fractures are associated with significant disability, high cost, and mortality. However, the exact biological mechanisms underlying susceptibility to hip fractures remain incompletely understood. To increase the understanding of the underlying mechanisms, we performed a meta-analysis of the associations between 4860 circulating proteins and risk of fractures using two large cohorts, including 6430 participants with 643 incident hip fractures. We identified 23 proteins/aptamers associated with incident hip fractures. Two proteins of the growth hormone/insulin growth factor system (GHR and IGFBP2), as well as GDF15 and EGFR were most strongly associated with hip fracture risk. High levels of several inflammation-related proteins were also associated with increased hip fracture risk. Pathway analysis identified reduced LXR/RXR activation and increased acute phase response signaling to be overrepresented among those proteins associated with increased hip fracture risk. Future mechanistic studies should investigate the underlying biology of these novel protein biomarkers which may be potential drug targets.

Identifiants

pubmed: 38477735
pii: 7505087
doi: 10.1093/jbmr/zjad011
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NHLBI NIH HHS
ID : HHSN268201200036C
Pays : United States
Organisme : NINDS NIH HHS
ID : R01AG023629
Pays : United States
Organisme : NIA NIH HHS
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research.

Auteurs

Thomas R Austin (TR)

Cardiovascular Health Research Unit, University of Washington, Seattle, WA, 98195, United States.

Howard A Fink (HA)

Geriatric Research Education and Clinical Center, VA Health Care System, Minneapolis, MN, 56401, United States.

Diana I Jalal (DI)

Division of Nephrology, Department of Internal Medicine, Carver College of Medicine, Iowa City, IA, 52242, United States.
Iowa City VA Medical Center, Iowa City, IA, 52246, United States.

Anna E Törnqvist (AE)

Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Osteoporosis Centre, Centre for Bone and Arthritis Research at the Sahlgrenska Academy, University of Gothenburg, 413 45, Gothenburg, Sweden.

Petra Buzkova (P)

Department of Biostatistics, University of Washington, Seattle, WA, 98115, United States.

Joshua I Barzilay (JI)

Division of Endocrinology, Kaiser Permanente of Georgia, Atlanta, GA, 30339, United States.

Tianyuan Lu (T)

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada.
Quantitative Life Sciences Program, McGill University, Montreal, Quebec, H3G 0B1, Canada.
5 Prime Sciences Inc, Montreal, Quebec, H3Y 2W4, Canada.

Laura Carbone (L)

Charlie Norwood VAMC, Augusta, GA, 30901, United States.
Department of Medicine, Medical College of Georgia, Augusta University, Augusta, GA, 30912, United States.

Maiken E Gabrielsen (ME)

Department of Public Health and Nursing, K.G. Jebsen Center for Genetic Epidemiology, Norwegian University of Science and Technology, 7491, Trondheim, Norway.

Louise Grahnemo (L)

Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Osteoporosis Centre, Centre for Bone and Arthritis Research at the Sahlgrenska Academy, University of Gothenburg, 413 45, Gothenburg, Sweden.

Kristian Hveem (K)

Department of Public Health and Nursing, K.G. Jebsen Center for Genetic Epidemiology, Norwegian University of Science and Technology, 7491, Trondheim, Norway.
HUNT Research Centre, NTNU, 7600, Levanger, Norway.

Christian Jonasson (C)

Department of Public Health and Nursing, K.G. Jebsen Center for Genetic Epidemiology, Norwegian University of Science and Technology, 7491, Trondheim, Norway.

Jorge R Kizer (JR)

Cardiology Section, San Francisco VA Health Care System, San Francisco, CA, 94121, United States.
Department of Medicine, Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, 94158, United States.

Arnulf Langhammer (A)

HUNT Research Centre, NTNU, 7600, Levanger, Norway.
Levanger Hospital, Nord-Trøndelag Hospital Trust, 7600, Levanger, Norway.

Kenneth J Mukamal (KJ)

Department of Medicine, Beth Israel Deaconess Medical Center, Brookline, MA, 2446, United States.

Robert E Gerszten (RE)

Department of Medicine, Beth Israel Deaconess Medical Center, Brookline, MA, 2446, United States.

Maria Nethander (M)

Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Osteoporosis Centre, Centre for Bone and Arthritis Research at the Sahlgrenska Academy, University of Gothenburg, 413 45, Gothenburg, Sweden.
Bioinformatics and Data Center, Sahlgrenska Academy, University of Gothenburg, 413 90, Gothenburg, Sweden.

Bruce M Psaty (BM)

Cardiovascular Health Research Unit, University of Washington, Seattle, WA, 98195, United States.
Departments of Medicine, Epidemiology, and Health Systems and Population Health, University of Washington, Seattle, WA, 98195, United States.

John A Robbins (JA)

Department of Medicine, University of California, Davis, CA, 95817, United States.

Yan V Sun (YV)

Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, 30322, United States.

Anne Heidi Skogholt (AH)

Department of Public Health and Nursing, K.G. Jebsen Center for Genetic Epidemiology, Norwegian University of Science and Technology, 7491, Trondheim, Norway.

Bjørn Olav Åsvold (BO)

Department of Public Health and Nursing, K.G. Jebsen Center for Genetic Epidemiology, Norwegian University of Science and Technology, 7491, Trondheim, Norway.
Department of Endocrinology, Clinic of Medicine, St. Olavs Hospital, Trondheim University Hospital, 7491, Trondheim, Norway.

Rodrigo J Valderrabano (RJ)

Research Program in Men's Health, Aging and Metabolism, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, 2130, United States.

Jie Zheng (J)

Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Jiao Tong University School of Medicine, Ruijin Hospital, Shanghai, 200025, China.
Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Shanghai National Clinical Research Center for Metabolic Diseases, Shanghai Digital Medicine Innovation Center, Shanghai Jiao Tong University School of Medicine, Ruijin Hospital, Shanghai, 200025, China.
MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of Bristol, Oakfield House, Bristol, BS8 2BN, United Kingdom.

J Brent Richards (JB)

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada.
5 Prime Sciences Inc, Montreal, Quebec, H3Y 2W4, Canada.
Department of Human Genetics, McGill University, Montreal, Quebec, Canada.
Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada.
Department of Medicine, McGill University, Montreal, Quebec, H4A 3J1, Canada.
Department of Twin Research, King's College London, London, SE1 7EH, United Kingdom.

Eivind Coward (E)

Department of Public Health and Nursing, K.G. Jebsen Center for Genetic Epidemiology, Norwegian University of Science and Technology, 7491, Trondheim, Norway.

Claes Ohlsson (C)

Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Osteoporosis Centre, Centre for Bone and Arthritis Research at the Sahlgrenska Academy, University of Gothenburg, 413 45, Gothenburg, Sweden.
Department of Drug Treatment, Region Västra Götaland, Sahlgrenska University Hospital, 413 45, Gothenburg, Sweden.

Classifications MeSH